Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection

NCT04282902 is registered in ClinicalTrials.gov with Huilan Zhang as lead sponsor.

NCT NCT04282902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04282902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection
Lead sponsor
Huilan Zhang
Phase
Phase 3
Overall status
Unknown status
Start date
February 4, 2020
Completion date
June 1, 2020
Enrollment
294 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

novel coronavirus pneumonia, pirfenidone, pneumonia